Mesothelioma Chemotherapy

In February 2004, the Food and Drug Administration approved the use of Pemetrexed for the treatment of malignant pleural mesothelioma. The use of this drug is approved in Europe since 2005. The addition of bevacizumab to chemotherapy (gemcitabine + cisplatin) proved to be disappointing. A European trial (IFCT-0701 MAPS) is ongoing to assess the interest of bevacizumb in combination with standard chemotherapy (pemetrexed + cisplatin). Other protocols have been tested with moderate efficacy, survival compared to more conventional treatment does not exceed a few months